319 research outputs found
d-dimensional non-asymptotically flat thin-shell wormholes in Einstein-Yang-Mills-Dilaton gravity
Thin-shell wormholes in Einstein-Yang-Mills-dilaton (EYMD) gravity are
considered. We show that a non-asymptotically flat (NAF) black hole solution of
the d-dimensional EYMD theory provides stable thin-shell wormholes which are
supported entirely by exotic matter. The presence of dilaton makes the
spacetime naturally NAF, and with our conclusion it remains still open to
construct wormholes supported by normal matter between two such spacetimes.Comment: 6 pages, 5 figures. Title changed, the first version has been
generalized to d-dimensions. The EYMGB part was removed and was considered in
a more general form separately in arXiv:1007.462
Extramedullary disease in multiple myeloma: a systematic literature review
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes
Extramedullary disease in multiple myeloma: a systematic literature review
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes
Heralded quantum entanglement between two crystals
Quantum networks require the crucial ability to entangle quantum nodes. A
prominent example is the quantum repeater which allows overcoming the distance
barrier of direct transmission of single photons, provided remote quantum
memories can be entangled in a heralded fashion. Here we report the observation
of heralded entanglement between two ensembles of rare-earth-ions doped into
separate crystals. A heralded single photon is sent through a 50/50
beamsplitter, creating a single-photon entangled state delocalized between two
spatial modes. The quantum state of each mode is subsequently mapped onto a
crystal, leading to an entangled state consisting of a single collective
excitation delocalized between two crystals. This entanglement is revealed by
mapping it back to optical modes and by estimating the concurrence of the
retrieved light state. Our results highlight the potential of rare-earth-ions
doped crystals for entangled quantum nodes and bring quantum networks based on
solid-state resources one step closer.Comment: 10 pages, 5 figure
Thin-shell wormholes from charged black holes in generalized dilaton-axion gravity
This paper discusses a new type of thin-shell wormhole constructed by
applying the cut-and-paste technique to two copies of a charged black hole in
generalized dilaton-axion gravity, which was inspired by low-energy string
theory. After analyzing various aspects of this thin-shell wormhole, we discuss
its stability to linearized spherically symmetric perturbations.Comment: Minor changes, 6 pages, 4 figures. Accepted for publication in Gen.
Rel. Gra
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
<p>Abstract</p> <p>Background</p> <p>Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies. The HSP90 family includes the cytosolic HSP90 (HSP90AA1), the ER paralogue gp96 (HSP90B1) and the mitochondrial member TRAP1 (HSP90L). We evaluated the <it>in vitro </it>anti-tumor activity and mechanism of action of PU-H71, a novel purine scaffold HSP90 inhibitor in human multiple myeloma cell lines.</p> <p>Methods</p> <p>Multiple human myeloma cell lines including cells that are resistant to corticosteroids and bortezimab were treated with PU-H71, followed by analysis of cell viability, cell cycle progression and apoptosis, by flow cytometry and caspase 3 immunoblot. Induction of unfolded protein response was studied by XBP-1 s immunoblot. The role of gp96 was further assessed by small hairpin RNA knockdown of gp96 before treatment with PU-H71.</p> <p>Results</p> <p>PU-H71 has potent <it>in vitro </it>anti-myeloma activity in both drug-sensitive and drug-resistant cell lines. PU-H71 activates the unfolded protein response and induces caspase-dependent apoptosis. The stable gp96 knockdown human myeloma cell line was found to be more resistant to PU-H71 and other HSP90 inhibitors including 17-AAG and 17-DMAG, even though these cells are more sensitive to conventional anti-myeloma drugs.</p> <p>Conclusion</p> <p>We conclude that PU-H71 is a promising drug for the treatment of myeloma. Our finding further suggests that PU-H71 and the geldanamycin analogues work in part by inhibiting the endoplasmic reticulum gp96 along with the cytosolic HSP90.</p
- …